
Growth-Accommodating Medtech: How Expandable Scaffolds Disrupt Congenital Surgical Cycles
Dr. Dereck Mush, MD, MBAEdwards Lifesciences is a medical device company focused on structural heart disease, including transcatheter and surgical heart valves.
Edwards Lifesciences develops structural heart technologies, led by transcatheter aortic valve replacement (TAVR). On 1 October 2026 the FDA approved its AUTUS Size-Adjustable Valve, a pulmonary valve for children that can be widened through a catheter procedure as the child grows. The company is listed on the New York Stock Exchange as EW. In the third quarter of 2026 it reported total sales of $1.72 billion, up 10.5 percent, including TAVR sales of $1.24 billion. Bernard J. Zovighian is Chief Executive Officer.
Leadership as of 14 November 2026.
Chief Executive Officer
How Edwards Lifesciences got here, step by step.
1 October 2026
The FDA approved Edwards Lifesciences' AUTUS Size-Adjustable Valve for pediatric patients, a pulmonary valve that can be widened through a catheter procedure as a child grows.
October 2026
Edwards reported third quarter 2026 total sales of $1.72 billion, up 10.5 percent.
Reported October 2026

Dr. Dereck Mush, MD, MBAMentions Edwards Lifesciences
Related companies
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: